Browsing Tag

Atreca

Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Jason Junior Oct 6, 2022

SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…

Health

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Jason Junior Jun 17, 2022

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…

Health

Atreca to Present at Upcoming Investor Conferences

Jason Junior May 20, 2022

SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…

Health

Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune…

Jason Junior May 5, 2022

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…

Health

Atreca Announces Expansion of Preclinical Pipeline

Jason Junior Apr 6, 2022

Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled for today at 4:15 p.m. EDT SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) --…

Health

Atreca Reports Fourth Quarter and Full-Year 2021 Financial Results and ATRC-101 Data Update

Jason Junior Mar 4, 2022

Partial response (PR) observed in ATRC-101 monotherapy cohort as well as a confirmed complete response (CR) observed in pembrolizumab combination cohort in Phase 1b clinical trial Clinical activity observed in multiple tumor types and…

Health

Atreca to Present at Upcoming Virtual Investor Conferences

Jason Junior Nov 9, 2021

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…

Health

Atreca Presents Initial Clinical Data from Phase 1b Trial of ATRC-101 in Select Advanced Solid…

Jason Junior Jul 29, 2021

Completed dose escalation portion of Phase 1b trial; ATRC-101 was well-tolerated with no dose-limiting toxicities observed Disease control associated with ATRC-101 target expression; preliminary biomarker data support the proposed…

Health

Atreca to Host Webcast Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101

Jason Junior Jul 27, 2021

SAN CARLOS, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on…